Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tacalcitol

D C Peters1, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Tacalcitol, a vitamin D3 analogue, effectively treats psoriasis by inhibiting keratinocyte proliferation and modulating skin inflammation. This topical treatment shows comparable efficacy to betamethasone valerate with minimal systemic absorption and no significant impact on calcium levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Analysis of residual coronary artery motion for breath hold and navigator approaches using real-time coronary MRI.

Magnetic resonance in medicine·2006
Same author

Topical eflornithine.

American journal of clinical dermatology·2001
Same author

Telithromycin.

Drugs·2001
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Dermatology
  • Pharmacology
  • Immunology

Background:

  • Tacalcitol is a vitamin D3 analogue available as topical ointments.
  • It is formulated in different concentrations for Japan (2 mcg/g, twice daily) and Western markets (4 mcg/g, once daily).
  • Tacalcitol influences keratinocyte behavior and modulates inflammatory mediators relevant to psoriasis.

Purpose of the Study:

  • To evaluate the efficacy and safety of topical tacalcitol in managing psoriasis.
  • To compare tacalcitol's efficacy with a standard topical corticosteroid.

Main Methods:

  • Clinical trials were conducted using topical tacalcitol ointments.
  • Efficacy was assessed in patients with stable plaque psoriasis and possibly pustular psoriasis.
  • Safety evaluations included monitoring for systemic absorption, hypercalcemia, and hypercalciuria.

Related Experiment Videos

Main Results:

  • Topical tacalcitol demonstrated effectiveness in managing stable plaque psoriasis.
  • Its efficacy was found to be similar to that of topical betamethasone valerate.
  • No significant systemic absorption, hypercalcemia, or hypercalciuria were observed with 4 mcg/g ointment used once daily for up to 8 weeks.
  • Mild local skin irritation was reported in up to 12% of patients.

Conclusions:

  • Topical tacalcitol is an effective therapeutic option for plaque psoriasis.
  • It offers a favorable safety profile with minimal systemic effects.
  • Tacalcitol represents a viable alternative to topical corticosteroids for psoriasis management.